The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Rapid Response Innovation Awards, 2011Ability of a Mitochondria Improver, Berberine, to Attenuate Parkinson's Disease
Objective/Rationale:
Mitochondrial dysfunction is a central modification underlying the damage of dopamine neurons in Parkinson’s disease (PD). Our hypothesis is that drugs able to stabilise... -
Rapid Response Innovation Awards, 2011Alpha-synuclein May Be Responsible for the Link Between Parkinson's Disease and Melanoma
Objective/Rationale:
Although the association between Parkinson’s disease (PD) and melanoma has been well established, biological explanations are still lacking. PD-causing gene alpha-synuclein is... -
MJFF Research Grant, 2011Identification of Nrf2 Activators Using an In Silico Modeling Platform, Followed by Evaluation of These Compounds in an Alpha-Synuclein Model of PD
Objective/Rationale:
Oxidative stress has been implicated in the etiology of Parkinson’s disease (PD). Under such conditions, the transcription factor NF-E2-related factor (Nrf2) binds to antioxidant... -
MJFF Research Grant, 2011LRRK2 GTPase Validation and Inhibitor Discovery
Objective/Rationale:
Mutations have been found in two places in the LRRK2 protein in patients with familial Parkinson’s disease. These LRRK2 mutations cause increased LRRK2 protein activity, leading... -
Target Validation, 2011Inhibition of LINGO-1 as a Novel Target for Regeneration in Pre-clinical PD Models
Objective/Rationale:
LINGO-1 inhibits growth responses in the central nervous system and LINGO-1 expression is increased when nerve cells are exposed to injury. We have shown that LINGO-1 expression... -
Target Validation, 2011Evaluation of ATP13A2 as a Molecular Target for Ameliorating Alpha-Synuclein-Induced Neurodegeneration in Pre-clinical Models of PD
Objective/Rationale:
Mutations in the alpha-synuclein gene cause autosomal dominant Parkinson’s disease. While mutant forms of alpha-synuclein are toxic when introduced into neurons and pre-clinical...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.